$70.00Original price was: $70.00.$46.00Current price is: $46.00.
CJC-1295 No DAC is a truncated peptide analogue of growth hormone releasing hormone (GHRH). First developed in the 1980s, research studies with modGRF have shown it to improve muscle repair and growth, accelerate wound healing, strengthen bones, increase fat burning, and improve metabolism. It may also have beneficial effects on blood sugar regulation and the immune system.
CJC-1295 (without DAC) is typically administered 1–2 times daily due to its shorter half-life and rapid clearance. A standard starting dose is 100 mcg (0.1 ml) taken once daily, ideally at night before sleep. For increased GH pulse stimulation, the dose may be increased to 200 mcg (0.2 ml), given either once or twice per day (morning and evening).
A common escalating dosing schedule may include:
Week 1–2: 100 mcg (0.1 ml) once daily at night
Week 3–4: Increase to 100 mcg twice daily (morning and night)
Week 5+: 200 mcg once or twice daily depending on goals
Because this peptide is rapidly cleared from the system (half-life ~30 minutes), consistent daily use is key for maintaining endogenous growth hormone pulse stimulation. Subcutaneous injections should be administered to the lower abdomen or thigh, on an empty stomach, for optimal effect.
CJC-1295 (without DAC) is a synthetic Growth Hormone Releasing Hormone (GHRH 1-29) analog, designed to stimulate the anterior pituitary to release endogenous growth hormone (GH) in natural pulses. It is structurally similar to sermorelin, but with greater stability and potency.
Unlike CJC-1295 with DAC, this formulation does not include Drug Affinity Complex (DAC), meaning it has a much shorter half-life and requires more frequent administration to mimic physiological GH pulsatility. This makes it an ideal option for those seeking precise control over GH release timing, especially when combined with a GHRP like Ipamorelin.
CJC-1295 (without DAC) mimics endogenous GHRH, binding to receptors on the anterior pituitary and stimulating growth hormone secretion. Its short-acting profile produces a natural-like GH pulse, which promotes downstream production of IGF-1 from the liver.
Key effects include:
Stimulation of GH release without suppressing natural feedback loops
No impact on cortisol or prolactin levels
Enhances lipolysis, protein synthesis, and recovery
Supports collagen formation, joint repair, and improved sleep quality
When paired with GHRPs (like Ipamorelin), the combined effect is a synergistic GH surge, enhancing both pulse frequency and amplitude.
This compound is not recommended during pregnancy or lactation. While GH modulation plays a physiological role during pregnancy, the effects of exogenous GHRH analogs have not been evaluated in pregnant or nursing individuals.
CJC-1295 (without DAC) is not approved for pediatric use. While GH modulation can be therapeutic in GH-deficient children, use should be strictly supervised by a pediatric endocrinologist.
CJC-1295 (without DAC) is not approved by the FDA as a pharmaceutical drug. It is classified as an investigational compound, commonly used in compounding, functional medicine, and regenerative therapy protocols.
